Russia’s FMBA Unveils Enteromix: mRNA Cancer Vaccine Shows 80% Effectiveness in Preclinical Trials, Ready for Clinical use

New Delhi (India) September 8: The Federal Medical and Biological Agency (FMBA) announces a cancer vaccine created by Russian scientists. It is now being prepared for clinical usage.

FMBA Announces Breakthrough at Eastern Economic Forum

Veronika Skvortsova is the head of the FMBA. She made the statement during the Eastern Economic Forum.

The Enteromix vaccine is based on mRNA technology. It is also the basis for certain Covid-19 vaccines. mRNA vaccines instruct the body's cells to make proteins. They will initiate an immune response against cancer cells. This is opposed to the use of a weakened virus.

Dr. Yulia Mikhailova is a molecular oncologist associated with the research team. She says, “This is not a one-size-fits-all jab. Enteromix uses RNA extracted from the patient’s own tumour cells to teach their immune system how to attack the cancer.”

Preclinical Results Show Strong Safety and Effectiveness

According to Skvortsova, the vaccine has finished years of study, including the necessary three-year preclinical testing. The results of the trials confirm the vaccine's great effectiveness and safety even after repeated doses. In certain cases, depending on the kind of cancer, tumours may shrink or grow more slowly by 60% to 80%.

Colorectal, Brain, and Skin Cancers Among First Targets

This vaccine will initially target colorectal cancer. It is also known as large intestine cancer. There are also ongoing efforts to develop vaccinations against glioblastoma. It is a quickly spreading brain cancer. It will also include efforts against several forms of melanoma. This is a dangerous skin cancer that affects the eye, particularly ocular melanoma.

The statement was made at the 10th Eastern Economic Forum in Vladivostok. The meeting hosted over 8,400 people from more than 75 nations.

Enteromix is intended to be targeted and less painful. This is in contrast to conventional cancer treatments like chemotherapy or radiation. They will target both tumours and healthy cells.

Global Race in mRNA Cancer Vaccine Development

In the race, Russia is not alone. Global biotech companies, such as Moderna (USA), CureVac, and BioNTech (Germany), are also testing customized mRNA cancer vaccines for lung, melanoma, and pancreatic tumours. Some of these businesses have an advantage in terms of data accuracy and regulatory clearances in countries like the US and the EU because they have been participating in Phase II or III studies.